ストックスクリーナーアプリを入手
0.7779
4.43%
-0.0361
前日終値:
$0.814
開ける：
$0.8129
24時間の取引高:
220.54K
Relative Volume:
0.37
時価総額：
$19.36M
収益：
$411.00K
当期純損益:
$-4.85M
株価収益率:
-1.768
EPS:
-0.44
ネットキャッシュフロー:
$-4.88M
1週間 パフォーマンス:
+5.74%
1か月 パフォーマンス:
+46.52%
6か月 パフォーマンス:
-20.46%
1年 パフォーマンス:
-55.03%
1日の値動き範囲:
$0.7068
$0.814
1週間の範囲:
$0.7068
$0.8576
52週間の値動き範囲:
$0.46
$1.911
Lexaria Bioscience Corp Stock (LEXX) Company Profile
名前
Lexaria Bioscience Corp
セクター
電話
250-765-6424
住所
100 - 740 MCCURDY ROAD, KELOWNA
LEXX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7779 | 20.26M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexaria Bioscience Corp (LEXX) 最新ニュース
Is Lexaria Bioscience Corp. exposed to political riskTrade Analysis Report & Accurate Buy Signal Notifications - mfd.ru
Lexaria Bioscience Stock Price, News, Quote & History - Investing News Network
Investor Mood: Is Fiverr International Ltd. forming a breakout patternQuarterly Portfolio Report & Weekly High Potential Stock Alerts - baoquankhu1.vn
Lexaria Adds Six Global Patents, Reaches 60 Granted as It Rallies Shareholders Ahead of 2026 Meeting - The Globe and Mail
Lexaria reaches milestone with 60 patents granted worldwide By Investing.com - Investing.com Nigeria
Lexaria Bioscience Expands Global Patent Portfolio to 60 Granted Patents - citybuzz -
LEXX Strengthens Patent Portfolio with New International Approva - GuruFocus
Lexaria Awarded Six Additional Patents - Investing News Network
Lexaria reaches milestone with 60 patents granted worldwide - Investing.com
Drug delivery firm Lexaria now holds 60 patents in nicotine, hypertension, epilepsy, diabetes - Stock Titan
Aug Big Picture: Can Lexaria Bioscience Corp. ride the EV waveTrade Signal Summary & Fast Gaining Stock Reports - baoquankhu1.vn
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point - Investing News Network
Risk Check: Will Lexaria Bioscience Corp outperform small cap indexesWeekly Stock Report & Reliable Price Action Trade Plans - baoquankhu1.vn
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higherEarnings Summary Report & Fast Moving Market Watchlists - bollywoodhelpline.com
Should I trade or invest in Lexaria Bioscience Corp. Equity WarrantStock Surge & Risk Controlled Swing Trade Alerts - bollywoodhelpline.com
Aug Big Picture: What hedge funds are buying Lexaria Bioscience CorpEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Leaders: Can Lexaria Bioscience Corp ride the EV waveWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-01-15 23:22:36 - baoquankhu1.vn
Levels Update: What are Lexaria Bioscience Corp. Equity Warrant’s earnings expectationsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
Institution Moves: Is Lexaria Bioscience Corp stock a bargain at current levels2025 Valuation Update & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital - TipRanks
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs - Investing.com
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with Dehyd - GuruFocus
Lexaria Releases Annual Letter from the CEO - Investing News Network
Inside Lexaria's tests of oral GLP-1 drugs that cut side effects by up to 48% - Stock Titan
Lexaria Bioscience CEO Releases Annual Letter, Outlook for 2026 - Intellectia AI
Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone - MSN
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Will Lexaria Bioscience Corp. Equity Warrant stock maintain dividend yieldJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is Lexaria Bioscience Corp. Equity Warrant stock dividend yield sustainableJuly 2025 Action & Expert Approved Momentum Trade Ideas - Улправда
Why Lexaria Bioscience Corp. stock is seen as undervaluedTrade Analysis Summary & Community Supported Trade Ideas - ulpravda.ru
Why Lexaria Bioscience Corp. Equity Warrant stock could be next big winnerJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - Улправда
San Gabriel Valley Tribune - FinancialContent
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - ncnewsonline.com
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience Corp (LEXX) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):